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ABSTRACT

EFFCTS OF PD149163 ON SPATIAL WORKING AND REFERENCE MEMORY IN
RATS PERFORMING A RADIAL ARM MAZE TASK

By

Maureen Suzanne Donegan
The current study evaluated the cognitive-symptom efficacy of the neurotensin
analog PD149163 for the treatment of schizophrenia. Schizophrenia is a life-long
debilitating mental illness that affects 1% of the population world wide. The symptoms of
schizophrenia include positive and negative symptoms, as well as cognitive deficits.
Current drug treatments fail to improve these cognitive deficits. The current study used
20 male Sprague-Daley rats and a radial arm maze task to compare the effects of
PD149163, clozapine, and haloperidol on working memory and spatial reference
memory. To create deficits in working memory, all rats were given the memory
impairing drug dizocilpine (MK-801) alone and in combination. The number of working,
reference, and total memory errors was calculated. The results show that MK801 did
significantly increase the number of working, reference, and total memory errors while
PD149163 had no effect on memory. Haloperidol had a trend of increasing reference
memory errors and clozapine had a trend of increasing working memory errors. None of
the drugs were able to reverse the strong memory impairing effect of MK801. The fact
that PD149163 did not increase errors in the maze suggest that the effects of PD149163
should be explored in other areas of cognition, such as attention.
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INTRODUCTION

Schizophrenia is a debilitating psychological disorder that often requires intensive
care. The disorder is not only detrimental to the people who have it but also to the society
at large, because most individuals with schizophrenia are unable to keep a job and end up
relying on government welfare and healthcare (Perkins & Rinaldi, 2002). The number of
people affected with schizophrenia is large, two to three million individuals in the U.S.,
and roughly 1% of the global population (Cáceda, Kinkead, & Nemeroff, 2006; Regier et
al., 1993). The symptoms of schizophrenia first show up during the late teens or early
20’s and they must be managed for the rest of one’s life, since there is no cure for this
devastating illness.
The symptoms of schizophrenia are labeled as both positive and negative. Positive
symptoms refer to the presence of abnormal behavior, while negative symptoms refer to
the absence of normal behavior. Psychologists in the United States use the Diagnostic and
Statistics Manual IV-Text Revision (2000) to diagnosis patients with schizophrenia.
Positive symptoms listed in the DSM-IV-TR include hallucinations and delusions.
Negative symptoms include social withdrawal, reduced affect or emotional
responsiveness, and reduced movement. Positive symptoms, such as hallucinations, are
thought to occur in schizophrenia patients due to distortions in mental imagery and errors
in sensory gating. These errors lead to difficulty in distinguishing between internally
generated and externally presented information (Aleman, Böcker., Hijman, de Haan, &
Kahn, 2003). Aleman et al. (2003) also believe perception in schizophrenia is heavily
influenced by top-down sensory processes which could alter incoming sensory
1

information and cause hallucinations. On the other hand, negative symptoms can be a
result of co-occurring depression and have been attributed to a variety of causes such as
structural brain abnormalities, enlarged ventricles (Andreasen, Flaum, Swayze, Tyrrell, &
Arndt, 1990), attenuation of the excitatory glutamate neurotransmission (Heresco-Levy et
al., 1999), and even chronic use of antipsychotic drugs.
Types of Schizophrenia
Schizophrenia is listed as a spectrum disorder with five sub classifications in the
DSM-IV-TR. These sub classifications depend on both positive and negative symptoms
and to what degree they are exhibited in the patient. The five sub classifications of
schizophrenia are: Paranoid type, Catatonic type, Disorganized type, Undifferentiated
type, and a Residual type. Individuals with paranoid schizophrenia exhibit mainly
positive symptoms, which could include auditory hallucinations and delusions about
people trying to hurt them or plot against them. A patient with catatonic schizophrenia
exhibits negative symptoms and suffers from extreme disturbances in movement. These
disturbances consist of periods of little movement, called catatonic stupor, followed by
hyperactivity. A person with catatonic schizophrenia may also display stereotypic
behavior by repeatedly making the same movements. People diagnosed with disorganized
schizophrenia display chaotic behaviors and have trouble completing simple tasks. Their
behaviors consist of positive and negative symptoms. Disorganized schizophrenia
patients also suffer from impairments in communication and emotional expression and
often act inappropriately. Undifferentiated schizophrenia is a diagnosis for people who
do not fit into any of the other groups and their symptoms may fluctuate over time.
Residual type schizophrenia is a diagnosis that is used when a patient does not exhibit
2

positive symptoms of schizophrenia but still shows some of the negative symptoms, such
as decreased emotional affect (Bengston., 2006).
Cognitive Impairment
Although the diagnosis of schizophrenia is based on the presence of positive or
negative symptoms, people diagnosed with schizophrenia also have severe cognitive
impairments (Goldman-Rakic, Castner, Svensson, Siever, & Williams, 2004; Green,
1996; Kaneda, Jayathilak, & Meltzer, 2010; Meltzer & McGurk, 1999; Silver, Feldman,
Bilker, & Gur, 2003; Woodward, Purdon, Meltzer, & Zald, 2005). Key cognitive
impairments occur for attention, perception, and executive functioning (Green &
Nuechterlein, 1999). These cognitive impairments can be observed in tests of verbal
learning and memory, verbal fluency, visual learning and memory, and working memory
(Silver et al., 2003). In a meta-analysis of over forty studies, Woodward et al. (2005)
stated that schizophrenia patients typically score more than one standard deviation below
the mean on many neuropsychological tests. In addition, several studies have concluded
that improvement in cognition is the best predictor of functional outcomes, which include
the ability to gain employment, daily living skills, social problem solving, and
psychosocial skill acquisition (Green, Kern, & Heaton, 2004; Kaneda et al., 2010;
Meltzer & McGurk, 1999; Woodward et al., 2005)
Functional outcomes like employment are a big concern for schizophrenia
patients because studies report that over 75% of schizophrenia patients are unemployed
(Kaneda et al., 2010; Mueser, Salyers, & Mueser, 2001). In one clinical study of 82
schizophrenia patients, only 15 patients or 18.3% were employed full-time (Meltzer,
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Thompson, Lee, & Ranjan, 1996). In addition, a 10 year longitudinal study of people
with schizophrenia reported that the unemployment rate increased from 88% in 1990 to
96% in 1999, despite the number of work programs for mental health patients in the area
increasing (Perkins & Rinaldi, 2002). These studies show that unemployment is a serious
problem for people diagnosed with schizophrenia. In addition to a lack of income,
unemployment can cause more stress and leave the patient without status, identity, daily
structure, or social support (Perkins & Rinaldi, 2002). Treatment for schizophrenia needs
to be improved so that patients seeking part or full-time employment may obtain it. If
more patients with schizophrenia are able to maintain employment, then less frequent
hospital stays and lower rates of suicide are expected (Kaneda et al., 2010). Therefore
new drug development for schizophrenia needs to focus on restoring cognitive function to
schizophrenia patients so that they may improve their quality of life and succeed in
society (Goldman-Rakic et al., 2004).
Drug Treatment
Typical antipsychotics. Chlorpromazine became the first antipsychotic drug after
its antipsychotic effects were fortuitously observed. It was developed in 1950 as a preanesthetic drug, but when given to psychiatric patients, it was found to have a calming
effect on those with schizophrenia (Meyer & Simpson, 1997). Several other drugs
similar to chlorpromazine were developed in the following years and these drugs became
known as “typical” antipsychotics. All typical antipsychotics are dopamine D2 receptor
antagonists. Although these drugs reduce positive symptoms of schizophrenia by
decreasing dopamine activity they also can cause adverse side effects through the same
mechanism.
4

Adverse side effects of typical antipsychotics. In schizophrenia, dopamine
neurons in the mesolimbic pathway, which runs from the ventral tegmental area to
various limbic structures, are suspected to be over active. The resulting over stimulation
of numerous limbic structures, including the amygdala and nucleus accumbens, is
thought to be the cause of positive symptoms. However, the nigrostriatal dopamine
pathway is normal in schizophrenia patients. This pathway releases dopamine into the
basal ganglia which is an area important for controlling movement. Thus, the blockade
of D2 receptors in this pathway causes extrapyramidal side effects (EPS).
EPS is characterized by motor symptoms such as, muscle tremors, rigidity, slurred
speech and slowed movements (Kamin, Manwani, & Hughes, 2000; Meyer & Simpson,
1997). Akathisia is another characteristic of this disorder, resulting in restlessness and
pacing or rocking. Yet, these side effects were considered to be minimal when compared
to the reduction of positive symptoms in schizophrenia patients, and typical
antipsychotics continued to be widely prescribed in the 1950s and 1960s. These
symptoms are a direct result of antipsychotic drug therapy and can be eliminated if drug
treatment is discontinued (Kamin et al., 2000). However, when long-term use of typical
antipsychotics is stopped, schizophrenia patients may experience an EPS related
condition called tardive dyskinesia. Tardive dyskinesia is a hyperkinetic motor disorder,
characterized by repetitive, involuntary, and purposeless movements of the face and
mouth (Casey., 1990; Meyer & Simpson, 1997). Facial spasms are commonly observed
in patients with tardive dyskinesia, including movements of the jaw, tongue, or lips, such
as chewing, lip smacking, and puckering. This motor disorder can last for years after a
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patient stops taking typical antipsychotics and may be irreversible in a minority of
patients (Casey., 1990; Kane, 1988).
In addition, typical antipsychotic drugs may also produce neuroleptic malignant
syndrome. Symptoms of neuroleptic malignant syndrome include high fever, rapid heart
rate, changes in blood pressure, sweating, muscle rigidity and altered consciousness
(Levenson, 1985). These symptoms usually subside after a few days but can last as long
as a couple of weeks. Less severe adverse effects of typical antipsychotics include
infertility, disruptions in menstrual cycles, reduced lactation, loss of libido, and erectile
dysfunction (Halbreich, Kinon, Gilmore, & Kahn, 2003). These hormonal and sexual side
effects are caused by hyperprolactinemia, which is caused by elevated levels of prolactin
in the blood stream for long periods of time. This occurs during drug therapy with
typical antipsychotics because the glands from which prolactin is released are normally
inhibited by the activation of dopamine D2 receptors. However when these receptors are
blocked the glands are never inhibited and elevated prolactin levels result (Gudelsky &
Porter, 1980; Meltzer & Stahl, 1976). Studies using rats have shown that the typical
antipsychotic, haloperidol, elevated prolactin levels for up to 24 hours while the atypical
antipsychotic, clozapine, was shown to elevate prolactin levels for only 1-2 hours
(Gudelsky, 1981) indicating that typical antipsychotics may induce hyperprolactinemia
more easily in humans than atypical antipsychotics. Typical antipsychotics are effective
at reducing psychosis in schizophrenia patients but they create a multitude of other
adverse effects, some life-threatening, and therefore are less frequently prescribed than
the more recently developed class of “atypical” antipsychotic drugs.
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Atypical Antipsychotics. The first atypical antipsychotic, or second generation
antipsychotic, to be developed was clozapine in 1959. Clozapine was considered atypical
simply because it did not produce EPS. Clozapine’s behavioral profile is thought to be a
result of its high affinity for the serotonin 5-HT2A receptor and relatively weaker affinity
for the dopamine D2 receptors (Meltzer, Matsubara, & Lee, 1989). In addition, atypical
antipsychotics also bind to other receptors including adrenergic, cholinergic, and
histaminergic receptors (Schotte et al., 1996). Therefore it is evident that atypical
antipsychotic drugs have much more complex mechanisms of action than typical
antipsychotic drugs. The diversity in receptor affinities causes atypical antipsychotics to
have varying effects on positive and negative symptoms and cognitive functions. As a
result, some atypical antipsychotic drugs are best at alleviating positive symptoms while
others are best at treating negative symptoms and some aspects of cognitive impairment.
Once it was realized that this class of drugs not only reduced the positive symptoms of
schizophrenia but also minimized the negative symptoms with decreased side effects, it
became the pharmacological model for other antipsychotics (Meyer & Simpson, 1997).
Other common atypical antipsychotics developed with similar binding profiles to
clozapine include risperidone, olanzapine, ziprasidone, and quetiapine (Roth, Sheffler, &
Kroeze, 2004).
A new class of antipsychotic drugs is also being developed. The prototype drug
for this class is aripiprazole (Abilify) and is considered a third generation antipsychotic
drug because instead of acting as a dopamine D2 receptor antagonist it acts as a partial
agonist at dopamine D2 receptors (Burris et al., 2002). In the past, antagonistic drugs
were binding to the dopamine receptors and preventing other neurotransmitters from
7

binding there but not activating the receptor. Aripiprazole will bind to some of the
dopamine D2 receptors as a partial agonist and some of these receptors will be activated
causing changes in the brain. A similar drug, bifeprunox is also being studied in clinical
trials as a third generation antipsychotic drug for schizophrenia (Newman-Tancredi,
Cussac, & Depoortere, 2007). It remains to be seen how these drugs do in clinical trials
and on the pharmacology market.
Adverse side effects of atypical antipsychotics. Although atypical
antipsychotics are associated with a reduced risk of extrapyramidal side effects and
tardive dyskinesia, they still have other adverse effects. The first atypical antipsychotic,
clozapine, unexpectedly disrupted the immune system of several patients when it was
introduced to the European market in the 1970’s (Alvir, Lieberman, Safferman,
Schwimmer, & Schaaf, 1993). This potentially fatal adverse side effect is called
agranulocytosis, which is a reduction in white blood cell counts and reduced ability to
fight off infections. The occurrence of this side effect is rare, seen in 1-2% of patients,
and can be reversed if administration of clozapine is stopped but the risk was enough to
keep the FDA from allowing clozapine to be prescribed in the United States until 1990
(Alvir et al., 1993; Meyer & Simpson, 1997). Clozapine is now prescribed in the U.S. but
patients must have their white blood cell counts tested every week for the first six months
of treatment and biweekly thereafter (Kamin et al., 2000; Sedky, Shaughnessy, Hughes,
& Lippmann, 2005). One of the reasons clozapine is still on the market is because it has
shown to be superior to other antipsychotics in treating schizophrenia patients who are
treatment-resistant and/or suicidal (Meltzer et al., 2003).
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Atypical antipsychotic drugs, especially clozapine and olanzapine, also can cause
weight gain (Kroeze et al., 2003; Lambert, Chou, Chang, Tafesse, & Carson, 2005;
Wirshing et al., 1999). Kroeze et al. (2003) discovered that the strong affinity for the H1
histamine receptor as seen in clozapine and other antipsychotics is positively correlated
with weight gain in schizophrenia patients. Increased weight increases the risk for more
severe side effects such as hypertension, hyperglycemia, and in some cases type II
diabetes which is a serious health concerns for patients (Kroeze et al., 2003; Lambert et
al., 2005). In addition to weight gain, several atypical antipsychotics have an adverse
effect on the cardiovascular system called “QT interval prolongation” which is an
elongation of the heartbeat intervals. The QT prolongation is not life-threatening but it
can lead to a more serious condition called torsades de pointes which can cause sudden
cardiac arrest (Stollberger, Huber, & Finsterer, 2005; Zareba & Lin, 2003). These side
effects are serious and often have a negative effect on patients’ quality of life and
therefore alternative drug therapy with fewer side effects should be explored.
Cognitive impairments and antipsychotic drugs. An additional reason to look
for alternative treatment for schizophrenics, besides adverse side effects, is that the
current antipsychotic drugs fail to significantly improve cognitive impairments. Yet, as a
class, atypical antipsychotics have been reported to improve cognitive function more than
typical antipsychotics. Meltzer and McGurk (1999) assessed how the atypical
antipsychotic drugs, clozapine, risperidone, and olanzapine affected cognitive domains.
They found that while the atypical antipsychotic drugs where able to improve some
aspects of cognition in humans, none showed improvements for all cognitive domains.
Risperidone was shown to improve working memory, executive function and attention.
9

Clozapine improved attention and verbal fluency. Olanzapine improved verbal learning
and memory. However, neither clozapine nor olanzapine improved working memory.
This construct is considered to be a key factor in cognitive impairment in schizophrenia
and a good indicator for functional outcomes (Goldman-Rakic., 1991; Silver et al., 2003).
Research conducted with atypical antipsychotics have shown that they can improve
cognitive function but these improvements are modest and do not lead to improvements
in daily life skills or long-term employment (Green, Kern, Braff, & Mintz, 2000;
Woodward et al., 2005). The search for a medication that will treat all symptoms of
schizophrenia and rehabilitate patients must continue, but a difficulty for creating new
drug treatments is the unknown cause of schizophrenia.
Disease Models
While the cause of schizophrenia is not known, it has been determined to have a
genetic factor (Kendler, 1983, 1997; Petronis, Paterson, & Kennedy, 1999). As stated in
the introduction there is a 1% rate of prevalence or risk of having schizophrenia.
However this risk increases to about 2-4% when a close relative (aunt, uncle, cousin,
nephew or niece) has schizophrenia. Having a parent with schizophrenia increases the
risk to 13% and if both parents have schizophrenia their children have a 50% chance of
also suffering from the disorder (Gottesman, 1991). However, the probability of one
identical twin having schizophrenia if the other twin is diagnosed with schizophrenia is
only 50%, so the cause is not solely genetic but environmental as well. Environmental
factors, such as stress or illness, are considered to be triggers for individuals who are
already genetically predisposed for schizophrenia (Corcoran et al., 2003).
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Neurodevelopmental hypothesis. One hypothesis for the cause of schizophrenia
is the neurodevelopmental hypothesis (Petronis et al., 1999; Weinberger, 1987).
According to this hypothesis, the brain develops abnormally in schizophrenia patients.
These abnormalities include enlarged ventricles and reduced cortical volumes. In addition
many cortical regions are hypoactive in schizophrenia patients (Petronis et al., 1999).
Genetic researchers have shown that the DISC1 gene (disrupted in schizophrenia 1) may
be responsible for abnormalities in the brains of schizophrenia patients. This gene
modulates second messenger proteins which are responsible for neural progenitor
proliferation during embryonic brain development and in the adult hippocampus (Mao et
al., 2009). A mutation in this gene may cause abnormal neurodevelopment, leading to
schizophrenia.
The dopamine hypothesis. The dopamine hypothesis states the symptoms of
schizophrenia are caused by hyperdopaminergic activity. This hypothesis is based on
studies showing that antipsychotics drugs exert their antipsychotic effects by reducing
dopamine transmission in the brain. The origins of the dopamine hypothesis came from
reports of acute psychosis after amphetamine overdose that was indistinguishable from
paranoid schizophrenia. (Beamish & Kiloh, 1960; Greenwood, 1957; McConnell, 1961;
O'Flanagan & Taylor, 1950). Symptoms reported by McConnell (1961) included
disorders of thought, paranoid delusions, and auditory and visual hallucinations.
Amphetamine induces these symptoms by blocking the reuptake of monoamines in the
synapse causing an overall increase in the amount of monoamines in the brain.
In a discrimination study with rats, researchers demonstrated that the
interoceptive cues of amphetamine administration are regulated by the dopamine system
11

(Schechter & Cook, 1975). These researchers therefore suggest that dopamine mediates
amphetamine psychosis and paranoid schizophrenia. Other researchers confirmed that
haloperidol has a strong affinity for dopamine receptors specifically in the caudate
nucleus, putamen, globus pallidus, nucleus accumbens and amygdala (Creese, Burt, &
Snyder, 1975) . Furthermore, researchers established that antipsychotics, act as
antagonists, inhibiting the release of dopamine in rat striatal slices (Seeman & Lee,
1975). In a review of the dopamine hypothesis, Meltzer and Stahl (1976) suggest that
schizophrenia is caused by too much dopamine in brain, particularly in the mesolimbic
dopamine pathway, which originates in ventral tegmental area and projects to various
regions in the limbic system (Meltzer & Stahl, 1976).
Revisions to the dopamine hypothesis added that schizophrenia is caused by
increased dopamine in the limbic system but decreased dopamine in the prefrontal cortex
(Davis, Kahn, Ko, & Davidson, 1991; Howes & Kapur, 2009). Decreased activity in the
prefrontal cortex is called hypofrontality, and may account for many of the cognitive
deficits found in schizophrenia, such as impairments in working memory and attention
(Brozoski, Brown, Rosvold, & Goldman, 1979; Goldman-Rakic et al., 2004). The revised
dopamine hypothesis includes the idea that the mesocortical dopamine pathway, which
originates in the ventral tegmental area and projects to the prefrontal cortex, has
decreased dopamine release in people with schizophrenia (Davis et al., 1991). This
hypothesis predicts an inverse relationship between hyperdopaminergic activity in the
mesolimbic pathway and hypodopaminergic activity in the mesocortical pathway,
resulting in a surplus of dopamine in the limbic pathway and a lack of dopamine in the
prefrontal cortex. Using microdialysis, researchers found that administration of the
12

typical antipsychotic haloperidol had little effect on the dopamine concentration in the
prefrontal cortex, but administration of the atypical antipsychotic drug clozapine elevated
dopamine levels in the prefrontal cortex (Kuroki, Meltzer, & Ichikawa, 1999). These
findings possibly explain why atypical antipsychotic drugs are more effective than typical
antipsychotic drugs at reducing negative symptoms and cognitive impairment in
schizophrenia.
The glutamate hypothesis. The glutamate hypothesis evolved from case studies
of individuals who exhibited psychotic symptoms similar to schizophrenia after
overdosing on phencyclidine or ketamine (Allen & Young, 1978; Cohen, Rosenbaum,
Luby, & Gottlieb, 1962; Javitt & Zukin, 1991; Krystal et al., 1994). These drugs
noncompetitively block NMDA glutamate receptors and induce both positive and
negative symptoms of schizophrenia, as well as cognitive impairments, resulting in a
drug state closely resembling schizophrenia. The glutamate hypothesis of schizophrenia
proposes the pathology of schizophrenia is due to the hypofunction of NMDA glutamate
receptors (Marek et al., 2010; Paz, Tardito, Atzori, & Tseng, 2008; Tsai & Coyle, 2002).
As a result of NMDA receptor hypofunction there is decreased glutamate transmission
which could be responsible for dysregulation of the local circuits and long-loop pathways
between the prefrontal cortex and limbic structures (Marek et al., 2010).
Animal Models
Since schizophrenia is a uniquely human disorder, models have been made to
predict the antipsychotic effects of a drug in humans using rats that do not have
schizophrenic behavior. Other models induce psychotic-predictive behavior in rats that
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are similar to the behaviors exhibited by schizophrenics such as sensory gating deficits,
social withdrawal, and purposeless or stereotyped behavior. These models use drugs that
increase dopamine release (e.g. amphetamine) or block NMDA glutamate receptors (e.g.
PCP, Ketamine). A commonly used drug for induced psychosis in rats is dizocilpine
(MK-801) which is a NMDA glutamate receptor antagonist. It has been shown to
significantly impair sensorimotor gating in rats as well as working and reference memory
in radial arm maze tasks (Levin, Bettegowda, Weaver, & Christopher, 1998; Zhang et al.,
2005).
The radial arm maze is an apparatus used with rats or mice to asses working
memory, spatial reference memory, and long-term memory all of which are key factors in
cognitive functioning (Ortega-Alvaro, Gibert-Rahola, & Micó, 2006). The type of
memory being tested depends on the task. Most radial arm mazes consist of a center
platform and eight arms with food cups at the end. The walls around the maze typically
have visual cues to aid the rats in spatial navigation. The rats used in this task are
normally food deprived and the arms can be baited with food pellets in various patterns.
Two commonly used tasks are the 4x8 (win-stay) and the non-match to sample (winshift) task.
In the 4x8 task, the same four arms are baited each trial and a rat must remember
which arms are baited and enter only those arms. Re-entries to arms already visited are
considered errors of working memory and entries into arms not baited during training are
considered reference memory errors (Levin et al., 1998; Zhang et al., 2005).
In the non-match to sample task the rats only have access to four arms during the
first trial and in the second trial they must remember what arms they already went to and
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only enter the other four arms. Working and reference memory errors are counted the
same as in the 4x8 task. Drugs that have both positive and negative effects on memory
can be tested in the radial arm maze by using a test-retest paradigm and comparing the
number of errors made in each trial.
The typical antipsychotic, haloperidol, has been tested in the radial arm maze
alone and in combination with memory impairing drugs. When tested alone haloperidol
had no effect on acquisition of a radial arm task (Terry et al., 2007) or on retention in a
delayed non match to sample radial arm maze task (Wolff & Leander, 2003). When
tested in combination with another drug, haloperidol enhanced the disruptive effect of
alcohol and failed to reverse the memory deficits created by amphetamine (de Oliveira &
Nakamura-Palacios, 2003; Nagai et al., 2007).
Some atypical antipsychotics, which have shown to improve cognitive function,
have also been tested in the radial arm maze, but their effects on working memory and
reference memory have been inconclusive. In a different study, olanzapine and clozapine
were shown to have a negative effect on working memory following acute
administration, but the effect diminished with chronic administration (Ortega-Alvaro et
al., 2006). However in another study using a delayed non-match to sample task,
olanzapine (3 and 5 mg/kg) and risperidone (0.1mg/kg) reduced the number of errors in a
retention trial when administrated immediately after the information phase, while
clozapine and ziprasidone had no effect on memory retrieval (Wolff & Leander, 2003).
Researchers have continued to search for new antipsychotics which will consistently
improve multiple domains of cognitive functioning. Many new drugs have been tested
using these animal models of cognitive functioning. Although some promising results
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have been found, a treatment to improve all symptoms of schizophrenic, including
cognitive impairments, has not been found.

Neurotensin
A novel approach for treating schizophrenia. Neurotensin is a central nervous
system neuropeptide that has received interest for its potential antipsychotic and
cognitive enhancing abilities. Three different neurotensin receptors have been found in
the brain and have been named the NT1, NT2, and NT3 receptors (Binder, 2001; Vincent
JP, 1999). Researchers have found reduced numbers of neurotensin receptors in the
caudate nucleus, cingulate cortex, and prefrontal cortex of the postmortem brains of
schizophrenia patients (Lahti, Cochrane, Roberts, Conley, & Tamminga, 1998). In
addition, it has been reported that the concentration of neurotensin is deceased in the
cerebral spinal fluid of schizophrenia patients but increases after administration of
antipsychotic drugs (Binder, 2001; Cáceda et al., 2006; Sharma, Janicak, Bissette, &
Nemeroff, 1997). Sharma et al. (1997) also reported that an increase of neurotensin in
cerebral spinal fluid is positively correlated with improvements in negative symptoms of
schizophrenia. Based on these findings, the neurotensin system should be a target of
novel antipsychotics that seek to treat negative symptoms and cognitive deficits.
Enhancing the activity of neurotensin in schizophrenia patients by giving them an
analog of the peptide that can cross the blood-brain barrier may be clinically useful in
treating the negative symptoms and cognitive impairment in schizophrenia (Prus, Huang,
Li, Dai, & Meltzer, 2007). Neurotensin has been shown to have a regulatory role in the
release of dopamine and serotonin in the prefrontal cortex similar to atypical
antipsychotics. In one study, researchers demonstrated that local administration of
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neurotensin through microdialysis increases dopamine levels in the prefrontal cortex
(Petkova-Kirova et al., 2008). Other studies using local administration of neurotensin
have shown that microinjections of neurotensin directly into the ventral tegmental area
also increased dopamine levels in the prefrontal cortex (Sotty et al., 2000) as well as
increased dopamine metabolism in the NAC (Kalivas & Taylor, 1985). These effects are
similar to the response seen after the administration of atypical antipsychotic drugs
(McMahon, 2002). The ability of antipsychotic drugs to increase dopamine levels in the
prefrontal cortex is significant because it is believed to be a contributing factor for how
they improve cognitive functioning in schizophrenia patients (Meltzer & McGurk, 1999;
Woodward et al., 2005). Besides increasing the level of dopamine in the prefrontal
cortex, neurotensin also acts on the serotonin system in a similar way to atypical
antipsychotics.
Behavioral effects of neurotensin. The neurotensin analog PD149163, has been
designed as a neurotensin receptor agonist that can cross the blood-brain barrier and is
being tested in rats for its antipsychotic properties. The acoustic startle reflex is one of
many behavioral assays that test the effects of neurotensin or its analog on behavior. This
assay examines sensorimotor gating, which is the ability to filter incoming stimuli, by
measuring prepulse inhibition. It also has clinical relevancy because schizophrenia
patients have deficits in sensorimotor gating, which can be alleviated after treatment with
atypical antipsychotics (Cáceda et al., 2006). Researchers have shown that neurotensin
improves sensory gating when infused into the nucleus accumbens of rats and reverses
disruptions of prepulse inhibition caused by administration of amphetamine (Feifel,
Minor, Dulawa, & Swerdlow, 1997). Researchers have also used genetically modified
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rats, such as the Brattleboro strain, to observe deficits in PPI and test novel antipsychotics
for their ability to restore sensorimotor gating. In one study, researchers found that
PD149163 (1.0 and 3.0 mg/kg, s.c.) reversed the PPI deficits found in Brattleboro rats in
the same manner as clozapine (10 and 15 mg/kgl, s.c.) but not haloperidol (0.1, 0.5, 1.0
mg/kg, s.c.), which failed to improve PPI behavior and also produced catalepsy in the rats
at the 1 mg/kg dose (Feifel, Melendez, & Shilling, 2004).
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RATIONALE
The overall goal of the study was to determine if PD149163 should continue to be
explored as a novel antipsychotic that may have better functional outcomes than the
current drug treatments for schizophrenia .In order to evaluate the effects PD149163 on
working and reference memory, rats were trained to perform a 4x4 radial arm maze task.
The first goal of this investigation was to determine if PD149163 had any effect on
cognition in the radial arm maze. The second goal of this investigation was to determine
if PD149163 could reverse the cognitive deficits created by the administration of MK801.
The third goal of this investigation was to compare the effects of PD149163 to a typical
and atypical antipsychotic, haloperidol and clozapine, respectively.
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METHODS

Subjects
The experiment used twenty male Sprague-Dawley rats (Charles River Inc.,
Portage, MI). All subjects were individually housed in plastic cages in a room kept under
constant temperature conditions and a 12 hour light/dark cycle. The animals had free
access to water in their cages and food was restricted to 85% of their free feeding weights
in order to motivate the rats to perform the behavioral task for food rewards. All
procedures were approved by the Institutional Animal Care and Use Committee at
Northern Michigan University and were consistent with the recommendations provided in
the Guide for the Care and Use of Laboratory Animals.

Apparatus
A radial arm maze (Med Associates, St. Albans, VT) was used for the
experiments. The radial arm maze (RAM) had 8 arms (45.7cm x 10.16cm) and eight
automatic guillotine doors that projected from an octagonal central platform (152.4cm
x152.4 cm, height 45.7cm). The maze was elevated 79 cm above the ground. The maze
was made of clear polycarbonate, white polypropylene runway bases and an aluminum
frame. Black rubber was placed on top of the runways and in the center platform so that
the contrast between the maze and the rats was greater, thus allowing for better detection
and tracking of the rat by video camera. At the end of each arm was a food cup that could
be baited with food pellets (45mg). Visual cues, such as paper cut outs of shape, were
placed within and outside the maze to act as cues for spatial navigation. The trials were
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controlled by EthoVision XT Trial & Hardware Control Module (Noldus, Leesburg, VA).
Behavioral activity was tracked by a camera mounted above the maze and recorded by
Noldus video software. The researchers controlled the maze from the computer module
behind a blind.

Figure 1. A side view of the radial arm maze.

Training
Rats were habituated to the maze for two consecutive days. During habituation,
each rat was placed in the center platform and allowed to freely explore all of the arms.
Food pellets were randomly scattered throughout the maze and in the food cups located at
the end of each arm. Each habituation session lasted 10 minutes. After this, training
sessions began.
Each daily training session consisted of two identical trials. There was a 10 second
delay between when the rat was placed in the center platform and when the trial started to
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prevent any placement bias. During each trial every door was open but only four of the
eight arms were baited with a single food pellet in the food cup. The configuration of
baited arms was different (pseudorandom) for every rat to control for spatial and
olfactory cues but kept consistent for each individual animal through out training and
testing. The trial ended once the rat had either obtained every food pellet or five minutes
elapsed, whichever occurred first. In between trials the maze was cleaned with 20%
isopropyl alcohol to eliminate olfactory cues. The training criterion consisted of 3
consecutive trials with no more than one reference or working memory error (see table
for definitions).

Table 1: The dependent variables recorded are listed below
Variables

Definition

Working Memory Errors
Reference Memory Errors

Number of re-entries to an arm previously visited during
the same trial
Number of entries into unbaited arms

Total Memory Errors

Number of working + reference memory errors

Path Length

Distance travelled in centimeters

Velocity

Distance (cm) divided by total time (sec)

Test session time

Total time taken to complete test (sec)

Percent of time spent

Time spent immobile (sec) divided by test time (sec)

immobile
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Testing and Treatment Design
After meeting training criteria, test sessions began. A test session was only one
trial, but otherwise identical to a training session. Drug tests occurred on Tuesdays and
Fridays, with no experimental procedures occurring between test sessions. For testing, the
rats were randomly divided into two groups with ten rats each. Group one consisted for
rats 1-10 and group two consisted of rats 11-20. Group one was administered MK801
and PD149163 and their respective vehicles in a counterbalanced design to test the
effects of the drugs alone and in combination. In group two, a typical and atypical
antipsychotic, haloperidol and clozapine, were tested alone and in combination with MK801 as a comparison.
Table 2: Drugs and doses that were used in this experiment
Drug Name

MK-801

PD149163

Haloperidol

Clozapine

Dose
Pre-Injection
time
.07 mg/kg
s.c. + 30 min

Mechanism

Rationale

NMDA receptor
antagonist

0.0625, 0.125,
0.25 mg/kg
s.c. +30 min
0.03125, 0.0625
mg/kg
s.c. + 30 min
0.3125, 1.25
mg/kg
s.c. + 30 min

Neurotensin
analog

Produces
memory deficits.
The NT analog
will be tested to
see if it can
reverse these
memorydisruptive
effects.
Treatment being
studied

Typical
antipsychotic

Comparison drug

Atypical
antipsychotic

Comparison drug
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Data Analysis
The dependent variables in this study are similar to those assessed in other
studies. In most studies a reference memory error is recorded as an entry into an arm that
was not baited in the training period (Levin et al., 1998; Terry et al., 2007). In other
words, memory of the baited arms from the first trial is indicated by the rat entering only
those arms in the consecutive trials. Working memory errors are counted by the number
of times a rat re-enters an arm already visited in the same trial (Wolff & Leander, 2003).
The other dependent variables of this study that were also record in other studies were the
path length and test session time (Ortega-Alvaro et al., 2006; Wolff & Leander, 2003). In
addition to those two locomotor variables, the percent of time spent immobile and
velocity was also recorded using EthoVision tracking software. All variables were
expressed as means (+/- standard error of the mean [SEM]). There were two factors
assessed in every analysis, and the levels for each factor corresponded to the number of
doses, and vehicle, for each drug. One factor was the treatment drug, which consisted of
either PD149163, haloperidol, or clozapine. The other factor was MK801, which always
consisted of two levels, vehicle and a 0.07 mg/kg dose. Both factors were repeated
measures variables, and therefore a two-factor repeated measures analysis of variance test
was conducted. Statistically significant differences for either factor main effect or for an
interaction effect were further analyzed using a Tukey HSD multiple comparisons post
hoc test. All analyses were conducted using PASW Statistics version 18 (Chicago,
Illinois) for Microsoft Windows.
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RESULTS

Training
Of the initial ten animals obtained for each group only nine in group 1 and seven
in group 2 met the training criteria and were used for testing. Again, the training criteria
required each rat to make no more than one error over three consecutive trials. In group 1
the mean number of training days required to meet criteria was 30.89 days +/- 2.08
standard error of the mean [SEM]). In group 2 the mean number of training days required
to meet criteria was 36.29 days +/- 3.35 SEM). Rats that failed to meet the training
criteria after 50 days of training were removed from the study. This number of days
exceeded over two standard deviations from the mean number of trials needed to reach
criteria.
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PD149163 + MK801
Working memory errors. The effects of MK807 (vehicle [VEH] and 0.07
mg/kg) and PD149163 (VEH, 0.0625, 0.125, and 0.25 mg/kg) are shown in figure 2.
Treatment with a 0.07 mg/kg dose of MK801 produced a statistically significant increase
in working memory errors (mean [M] = 2.7 +\- 0.60) compared to vehicle (M= 0.64 +/0.19), (F[1, 8]=14.29, p<0.01, eta2=0.64). Moreover, MK801 treatment had a large
effect on working memory errors, accounting for 64% of the total variance. There was
not a statistically significant effect shown for the main effect of PD149163 treatment
(F[3, 24]=0.71, p>0.05, eta2=0.08) nor for the interaction effect (F[3, 24]=1.24, p>0.05,
eta2=0.13).

Working Memory Errors
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0
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Figure. 2 The effects of PD149163 + MK801 on mean (+/- SEM) number of working
memory errors.
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Reference memory errors. The effects of MK807 (VEH and 0.07 mg/kg) and
PD149163 (VEH, 0.0625, 0.125, and 0.25 mg/kg) are shown in figure 3. Treatment with
a 0.07 mg/kg dose of MK801 produced a statistically significant increase in reference
memory errors (M = 2.47 +\- 0.27) compared to vehicle (M= 1.50 +/- 0.2), (F[1,
8]=15.8, p<0.01, eta2=0.66). Moreover, MK801 treatment had a large effect on
reference memory errors, accounting for 66% of the total variance. There was not a
statistically significant effect shown for the main effect of PD149163 treatment (F[3,
24]=0.66, p>0.05, eta2=0.08) nor for the interaction effect (F[3, 24]=1.32, p>0.05,
eta2=0.14).

Reference Memory Errors
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Figure 3: The effects of PD149163 + MK801 on mean (+/- SEM) number of reference
memory errors.
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Total errors. The effects of MK807 (VEH and 0.07 mg/kg) and PD149163
(VEH, 0.0625, 0.125, and 0.25 mg/kg) are shown in figure 4. Treatment with a 0.07
mg/kg dose of MK801 produced a statistically significant increase in total memory errors
(M = 4.92 +\- 0.73) compared to vehicle (M= 2.14 +/- 0.26), (F[1, 8]=17.13, p<0.01,
eta2=0.68). Moreover, MK801 treatment had a large effect on total memory errors,
accounting for 68% of the total variance. There was not a statistically significant effect
shown for the main effect of PD149163 treatment (F[3, 24]=0.55, p>0.05, eta2=0.06)
nor for the interaction effect (F[3, 24]=0.07, p>0.05, eta2=0.008).
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Figure 4: The effects of PD149163 + MK801 on mean (+/- SEM) number of total
memory errors.
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Path length. The effects of MK807 (VEH and 0.07 mg/kg) and PD149163 (VEH,
0.0625, 0.125, and 0.25 mg/kg) are shown in table 3. Treatment with a 0.07 mg/kg dose
of MK801 produced a statistically significant increase in path length (M = 741.96 cm +\79.70 cm) compared to vehicle (M= 426.83 cm +/- 17.39 cm), (F[1, 8]=15.75, p<0.01,
eta2=0.66). Moreover, MK801 treatment had a large effect on path length, accounting
for 66% of the total variance. There was not a statistically significant effect shown for the
main effect of PD149163 treatment (F[3, 24]=0.53, p>0.05, eta2=0.06) nor for the
interaction effect (F[3, 24]=0.74, p>0.05, eta2=0.08).
Test session time. The effects of MK807 (VEH and 0.07 mg/kg) and PD149163
(VEH, 0.0625, 0.125, and 0.25 mg/kg) are shown in table 3. There was not a statistically
significant effect shown for the main effect of MK801 (F[1,8] =0.77, p>0.05, eta2=0.09
nor PD149163 treatment (F[3, 24]=0.88, p>0.05, eta2=0.10). There was a statistically
significant effect shown for the interaction effect (F[3, 24]=3.65, p<0.05, eta2=0.31).
Based upon a comparison between simple effect means using a Tukey post hoc multiple
comparisons test, statistically significant differences in test session times were not found
between these groups.
Velocity. The effects of MK807 (VEH and 0.07 mg/kg) and PD149163 (VEH,
0.0625, 0.125, and 0.25 mg/kg) are shown in table 3. Treatment with a 0.07 mg/kg dose
of MK801 produced a statistically significant increase in velocity (M = 14.98 cm/s +\0.83 cm/s) when compared to vehicle (M= 11.47 cm/s +/- 0.75 cm/s), (F[1, 8]=20.83,
p<0.01, eta2=0.72). Moreover, MK801 treatment had a large effect on velocity,
accounting for 72% of the total variance. There was not a statistically significant effect
shown for the main effect of PD149163 treatment (F[3, 24]=2.97, p>0.05, eta2=0.27).
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There was a statistically significant interaction effect (F[3, 24]=4.15, p<0.05,
eta2=0.34). Based upon a comparison between simple effect means using a Tukey post
hoc multiple comparisons test, significantly greater velocity was observed when rats were
treated with MK801 + PD149163 (0.0625mg/kg) (M= 14.36 cm/s) compared to when
rats were treated with VEH + PD149163 (0.0625 mg/kg) (M= 10.78 cm). Significantly
greater velocity also was shown, when rats were treated with MK801 + PD149163 (0.125
mg/kg) (M=15.18 cm/s) compared to VEH + PD149163 (0.125 mg/kg) (M=11.33cm/s),
and when rats were treated with MK801 + PD149163 (0.125 mg/kg) (M=15.26 cm/s)
compared to VEH + PD149163 (0.125 mg/kg) (M=9.24 cm/s). In addition, significantly
greater velocity was observed when rats were treated with VEH + VEH (M=14.52 cm/s)
compared to VEH + PD149163 (0.125 mg/kg) (M=9.24 cm/s). The interaction had a
large effect on velocity, accounting for 34% of the total variance.
Percent of time spent immobile. The effects of MK807 (VEH and 0.07 mg/kg)
and PD149163 (VEH, 0.0625, 0.125, and 0.25 mg/kg) are shown in table 3. There was
not a statistically significant effect shown for the main effect of MK801, (F[1, 8]=4.35,
p>0.05, eta2=0.35). There was a main effect of PD149163 treatment (F[3, 24]=3.33,
p<0.05, eta2=0.29). Based on the results from the ANOVA, statistically greater percent
of time spent immobile was observed when rats were treated with PD149163 (0.25
mg/kg) (M= 76.8% +\- 4.20%) compared to when rats were treated with PD149163 VEH
(M= 66.52% +/- 1.45%). Moreover, PD 149163 treatment had a large effect on time
spent immobile, accounting for 29% of the total variance. There was not a statistically
significant interaction effect (F[3, 24]=0.14, p>0.05, eta2=0.02). No other statistically
significant effects were found.
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Table 3.The effects of PD149163 and MK801 on locomotor activity.
Path Length
(cm)

Test session
time (s)

MK Dose (mg/kg)

VEH

0.07

VEH

PD Dose VEH
(mg/kg)
0.0625

412.21

Velocity
(cm/s)

Percent of time
spent immobile
(%)

0.07

VEH

0.07

VEH

0.07

789.86

29.75 56.70

14.52

15.11

68.74

64.30

520.97

780.50

49.27 56.95

10.78

14.36

74.96

70.44

0.125

455.31

736.40

42.25 51.06

11.33

15.18

73.21

67.26

0.25

462.82

661.08

61.55 44.43

9.24

15.26

80.41

73.21

31

Haloperidol + MK801
No omissions occurred during testing with dose combinations of haloperidol and MK801.
Working memory errors. The effects of MK807 (VEH and 0.07 mg/kg) and
haloperidol (VEH, 0.03125, and 0.0625 mg/kg) are shown in figure 5. Treatment with
dose combination of haloperidol and MK801 did not produced statistically significant
effects on working memory errors in this task, (main effect of haloperidol, F[2,12] =
0.36, p>0.05, eta²=0.06; main effect of MK801, F[1, 6]=5.22, p>0.05, eta2=0.47;
interaction effect, F[2,12]=1.49, p>0.05, eta2=0.20). Although no statistically significant
effects were found there were still large effect sizes for MK801 and the interaction,
which accounted for 47% and 20% of the variance, respectively.
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Fig. 5: The effects of haloperidol + MK801 on mean (+/- SEM) number of working
memory errors.
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Reference memory errors. The effects of MK807 (VEH and 0.07 mg/kg) and
haloperidol (VEH, 0.03125, and 0.0625 mg/kg) are shown in figure 6. Treatment with a
0.07 mg/kg dose of MK801 produced a statistically significant increase in reference
memory errors (M=2.71 +\- 0.14) compared to vehicle (M=1.52 +/- 0.12), (F[1,
6]=55.15, p<0.001, eta2=0.90). Moreover, MK801 treatment had a large effect on
reference memory errors, accounting for 90% of the total variance. There was not a
statistically significant effect shown for the main effect of haloperidol treatment (F[2,12]
=0.33, p>0.05, eta²=0.05) nor for the interaction effect (F[2,12]=0.27, p>0.05,
eta2=0.04).
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Fig. 6: The effects of haloperidol + MK801 on mean (+/- SEM) number of reference
memory errors.
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Total memory errors. The effects of MK807 (VEH and 0.07 mg/kg) and
haloperidol (VEH, 0.03125, and 0.0625 mg/kg) are shown in figure 7. Treatment with a
0.07 mg/kg dose of MK801 produced a statistically significant increase in total memory
errors (M=6.29 +\- 1.50) compared to vehicle (M=1.95 +/- 0.22), (F[1, 6]=7.30, p<0.05,
eta2=0.55). Moreover, MK801 treatment had a large effect on total memory errors,
accounting for 55% of the total variance. There was not a statistically significant effect
shown for the main effect of haloperidol treatment (F[2,12] =0.33, p>0.05, eta²=0.05)
nor for the interaction effect (F[2,12]=0.77, p>0.05, eta2=0.11).
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Fig.7: The effects of haloperidol + MK801 on mean (+/- SEM) number of total memory
errors.
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Path length. The effects of MK807 (VEH and 0.07 mg/kg) and haloperidol
(VEH, 0.03125, and 0.0625 mg/kg) are shown in table 4. Treatment with a 0.07 mg/kg
dose of MK801 produced a statistically significant increase in path length (M= 858.08 cm
+\- 123.54 cm) compared to vehicle (M=477.43 cm +/- 20.52 cm), F[1, 6]=10.24,
p<0.05, eta2=0.63). Moreover, MK801 treatment had a large effect on path length,
accounting for 63% of the total variance. There was not a statistically significant effect
shown for the main effect of haloperidol treatment (F[2, 12]=0.16, p>0.05, eta2=0.03)
nor for the interaction effect (F[2, 12]=0.74, p>0.05, eta2=0.11).
Test session time. The effects of MK807 (VEH and 0.07 mg/kg) and haloperidol
(VEH, 0.03125, and 0.0625 mg/kg) are shown in table 4. Treatment with a 0.07 mg/kg
dose of MK801 produced a statistically significant increase test session time (M= 59.09 s
+\- 6.70 s) compared to vehicle (M=33.43 s +/- 2.72 s), (F[1, 6]=10.53, p<0.05,
eta2=0.64). Moreover, MK801 treatment had a large effect on session time, accounting
for 64% of the total variance. There was not a statistically significant effect shown for the
main effect of haloperidol treatment (F[2, 12]=0.06, p>0.05, eta2=0.01) nor for the
interaction effect, F[2,12]= 1.10, p>0.05, eta2=0.36).
Velocity. The effects of MK807 (VEH and 0.07 mg/kg) and haloperidol (VEH,
0.03125, and 0.0625 mg/kg) are shown in table 4.Treatment with dose combinations of
haloperidol and MK801 did not produce statistically significant effects on velocity in this
task (main effect of MK801, F[1, 6]= 0.045, p > 0.05, eta2=0.01; main effect of
haloperidol, F[2, 12]=0.32, p>0.05, eta2=0.05; interaction effect, F[2, 12]= 0.17,
p>0.05, eta2=0.03). Based on the results from the ANOVA no statistically significant
differences in velocity were observed.
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Percent of time spent immobile. The effects of MK807 (VEH and 0.07 mg/kg)
and haloperidol (VEH, 0.03125, and 0.0625 mg/kg) are shown in table 4. Treatment with
dose combinations of haloperidol and MK801 did not produce statistically significant
effects on percent of time spent immobile in this task, (main effect of MK801, F[1, 4]=
0.004, p > 0.05, eta2=0.001; main effect of haloperidol, F[2, 8]=0.511, p>0.05,
eta2=0.113; interaction effect, F[2, 8]= 0.08, p>0.05, eta2=0.02). Based on the results
from the ANOVA no statistically significant differences in percent of time spent
immobile were observed.

Table 4: The effects of haloperidol and MK801 on locomotor activity.

MK Dose
(mg/kg)
Hal
VEH
Dose
(mg/kg) 0.03125
0.0625

Path Length
(cm)

Test session
time (s)

Velocity (cm/s)

Percent of time
spent immobile
(%)

VEH

VEH

VEH

VEH

0.07

0.07

0.07

0.07

471.99

841.49

30.16

58.82

15.25

14.60

66.25

68.28

529.80

730.92

41.93

52.50

14.04

14.57

73.32

69.96

430.49 1001.82

28.22

65.94

15.72

15.19

67.93

67.80
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CLOZAPINE+ MK801
No omissions occurred during testing with dose combination of haloperidol and MK801
Working memory errors. The effects of MK807 (VEH and 0.07 mg/kg) and
clozapine (VEH, 0.3125, and 1.25 mg/kg) are shown in figure 8. Treatment with a 0.07
mg/kg dose of MK801 produced a statistically significant increase in working memory
errors (M=3.00 +\- 0.72), compared to vehicle (M=1.24 +/- 0.58), (F[1, 6]=15.16,
p<0.01, eta2=0.72). Moreover, MK801 treatment had a large effect on working memory
errors, accounting for 72% of the total variance. There was not a statistically significant
effect shown for the main effect of clozapine treatment (F[2,12] = 0.32, p>0.05,
eta²=0.05) nor for the interaction effect (F[2,12]=0.84, p>0.05, eta2=0.12).
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Fig. 8: The effects of clozapine + MK801 on mean (+/- SEM) number of working
memory errors.
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Reference memory errors. The effects of MK807 (VEH and 0.07 mg/kg) and
clozapine (VEH, 0.3125, and 1.25 mg/kg) are shown in figure 9. Treatment with dose
combinations of MK801 and clozapine did not produce statistically significant effects on
reference memory errors in this task, (main effect of MK801, F[1, 6]=3.69, p>0.05,
main effect of clozapine, F[2,12] = 2.44, p>0.05, eta²=0.29; eta2=0.38; interaction
effect, F[2,12]=2.87, p>0.05, eta2=0.32). No statistically significant effects were found.
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Fig. 9: The effects of clozapine + MK801 on mean (+/- SEM) number of reference
memory errors.
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Total memory errors. The effects of MK807 (VEH and 0.07 mg/kg) and
clozapine (VEH, 0.3125, and 1.25 mg/kg) are shown in figure 10. Treatment with a 0.07
mg/kg dose of MK801 produced a statistically significant increase in total memory errors
(M=5.76+\- 0.81), compared to vehicle (M= 2.81+/- 0.78), (F[1, 6]=17.45, p<0.01,
eta2=0.74). Moreover, MK801 treatment had a large effect on total memory errors,
accounting for 74% of the total variance. There was not a statistically significant effect
shown for the main effect of clozapine treatment (F[2,12] = 0.80, p>0.05, eta²=0.12) nor
for the interaction effect (F[2,12]=1.73, p>0.05, eta2=0.22).
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Fig. 10: The effects of clozapine + MK801 on mean (+/- SEM) number of total memory
errors.
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Path length. The effects of MK807 (VEH and 0.07 mg/kg) and clozapine (VEH,
0.3125, and 1.25 mg/kg) are shown in table 5. Treatment with a 0.07 mg/kg dose of
MK801 produced a statistically significant increase in path length (M= 700.62 cm +\43.20 cm) compared to vehicle (M=530.40 cm +/- 63.59 cm), F[1, 6]=6.01, p=0.050,
eta2=0.50). Moreover, MK801 treatment had a large effect on path length, accounting for
50% of the total variance. There was not a statistically significant effect shown for the
main effect of clozapine treatment (F[2, 12]=2.01, p>0.05, eta2=0.25) nor for the
interaction effect (F[2,12]= 1.01, p>0.05, eta2=0.14).
Test session time. The effects of MK807 (VEH and 0.07 mg/kg) and clozapine
(VEH, 0.3125, and 1.25 mg/kg) are shown in table 5. Treatment with dose combinations
of clozapine and MK801 did not produce statistically significant effects on test session
time in this task, (main effect of MK801, F[1, 6]=0.16, p>0.05, eta2=0.03; main effect
of clozapine, F[2, 12]=3.28, p>0.05, eta2=0.35; interaction effect, F[2,12]= 1.60,
p>0.05, eta2=0.21).
Velocity. The effects of MK807 (VEH and 0.07 mg/kg) and clozapine (VEH,
0.3125, and 1.25 mg/kg) are shown in table 5. Treatment with dose combinations of
clozapine and MK801 did not produce statistically significant effects on velocity in this
task, (main effect of MK801, F[1, 6]=0.09, p>0.05, eta2=0.02; main effect of clozapine,
F[2, 12]=2.99, p>0.05, eta2=0.33; interaction effect, F[2,12]= 0.88, p>0.05, eta2=0.13).
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Percent of time spent immobile. The effects of MK807 (VEH and 0.07 mg/kg)
and clozapine (VEH, 0.3125, and 1.25 mg/kg) are shown in table 5. Treatment with dose
combinations of clozapine and MK801 did not produce statistically significant effects on
percent of time spent immobile in this task, (main effect of MK801, F[1, 6]=0.015,
p>0.05, eta2=0.003; main effect of clozapine, F[2, 12]=0.66, p>0.05, eta2=0.10;
interaction effect, F[2,12]= 0.17, p>0.05, eta2=0.03).

Table 5: The effects of clozapine and MK801 on locomotor activity.
Path Length
(cm)

Test session
time (s)

Velocity (cm/s) Percent of time
spent immobile
(%)

MK Dose (mg/kg)

VEH

0.07

VEH

VEH

Clozapine VEH
Dose
0.3125
(mg/kg)

425.09

653.61

12.77

25.27

15.76

14.04

70.57

71.57

445.77

739.42

5.11

12.69

13.97

15.10

73.30

71.87

720.33

708.83

7.79

11.92

12.20

13.60

75.45

76.80

1.25
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0.07

0.07

VEH

0.07

DISCUSSION

This study evaluated the effects of MK801, PD149163, haloperidol and clozapine
on performance in the radial arm maze task. The study demonstrated that administration
of MK-801 creates deficits in working, reference, and total errors made in a radial arm
maze task. These deficits proved to be hard to reverse. No drug combination with MK801 significantly reduced errors when compared to the number of errors made when MK801 was administered by itself. PD149163 failed to significantly improve or impair
memory in the radial arm maze. Haloperidol and clozapine also did not significantly
effect working, reference, or total memory errors.
Training
The training criteria for this study were similar to those used other studies (de
Oliveira & Nakamura-Palacios, 2003; Wolff & Leander, 2003; Zhang et al., 2005). The
rats were trained twice a day and could not make more than one error in three consecutive
trials before moving on to testing. The average number of training days required to meet
criteria was about 36 days. This was a greater number of training days required to meet
criteria than reported by Zhang (2005) who train rats to perform the same task in 15-20
sessions (2 trials per day). They used a similar radial arm maze but had a transparent
plastic octagonal hub blocking the arms instead of metal doors during the first 30 seconds
of each trial (Zhang & O'Donnell, 2000). This would have allowed the rats to see down
the arms before entering them and might have helped them orientate in the maze and
prevent making incorrect entries. In the first group only one rat, #7, failed to meet the
training criteria, but in the second group three rats, #12, #15, and #16, failed to meet the
42

training criteria. The removal of these animals reduced the sample size to nine for group
one and only seven for group two.
MK801
The positive and negative symptoms and cognitive impairment in schizophrenia
have been suggested to be caused by glutamate hypofunction, particularly in prefrontal
cortex (Marek et al., 2010; Paz et al., 2008; Tsai & Coyle, 2002). MK801 is an NMDA
glutamate antagonist and therefore blocks glutamate transmission causing glutamate
hypofuntion. After administration of MK801 rodents show behaviors that mimic
schizophrenic symptoms like stereotypy, social withdrawal, and deficits in prepulse
inhibition (Labonte, Bambico, & Gobbi, 2009). Furthermore, MK801 induces severe
cognitive deficits and has been used to model the symptoms of schizophrenia in rodents
(Rezvani et al., 2008). Other researchers (de Oliveira & Nakamura-Palacios, 2003;
Legault, Smith, & Beninger, 2006; Nagai et al., 2007) have used different drugs (i.e.
alcohol, scopolamine, and methamphetamine, respectively) to create memory
impairments in radial arm maze. Yet, the effects of MK801 on the glutamate system give
it the most face and construct validity as a pharmacological model of psychosis in
animals (Labonte et al., 2009) and it was chosen to model the cognitive deficits of
schizophrenia in this study. Ketamine, another NMDA glutamate receptor antagonist,
also produced MK-801-like deficits in cognition in animals (McGinnis, 2010) .
The results of this study show that MK801 produced a reliable deficit in working
and reference memory in the radial arm maze task, as seen in other studies (Levin et al.,
1998; Marcus et al., 2005; Zhang et al., 2005). Yet, none of the drugs tested in the current
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study reversed these MK-801-induced deficits. The dose chosen for MK801in the current
study, 0.07 mg/kg, is similar to the dose used in other cognition studies using rats. For
example, Levin et al. (1998) attenuated working and reference memory deficits induced
by a 0.1 mg/kg dose of MK801 using nicotine. Zhang (2005) on the other hand, used
inhibitors of the enzyme, type four phosphodiesterase, to enhance working and reference
memory that had been impaired by MK801 (0.1mg/kg) administration.
The effects of MK801 were not identical for each group tested in present study.
In group one MK801 (0.07 mg/kg) significantly increased working, reference, and total
errors. MK801 significantly increase path length and velocity in group one but not test
session time or percent of time spent immobile. In group two MK801 significantly
increased reference and total memory errors, but not working memory errors. MK801
significantly increased the path length and session time but did not effect velocity or
percent of time spent immobile. MK801 has been observed to cause significant
hyperactivity in some studies (Levin et al., 1998) but did not alter exploration time in
other studies (Zhang et al., 2005). The data from the present study indicates that 0.07
mg/kg of MK801 did not have an overall effect on locomotor behavior.
PD149163
PD149163 is an analog of neurotensin, a neuropeptide neurotransmitter.
Neurotensin binds to receptors in the brain that are co-localized with dopamine receptors
and modulates dopaminergic transmission (Binder, 2001). More specifically, neurotensin
acts as an antagonist at D2 receptors through several possible mechanisms and may be an
endogenous antipsychotic (Cáceda et al., 2006). In fact, patients with schizophrenia have
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low concentrations of neurotensin in their CSF and the neurotensin system has been
hypothesized to be dysregulated in schizophrenia (Cáceda et al., 2006; Sharma et al.,
1997). When administered to rodents, neurotensin analogs like PD149163 have shown
similar effects to antipsychotic drugs in several behavioral tasks. For example,
neurotensin analogs and neurotensin itself have been shown to prevent condition
avoidance responding in a similar manner to other atypical antipsychotics when
administered systemically and intracerebroventrically, respectively (Holly, Ebrecht, &
Prus, 2010; Luttinger, Nemeroff, & Prange, 1982) In addition, PD149163 reversed a
pharmacologically induced impairment in prepulse inhibition which is a measure of
sensorimotor gating, a core deficit in schizophrenia (Feifel et al., 2009), as well as
blocking fear-potentiated startle (Shilling & Feifel, 2008). It also has been shown to
reverse scopolamine-induced deficits in a novel object discrimination task of working
memory (Azmi, Norman, Spicer, & Bennett., 2006). Based on these previous studies it
was hypothesized that PD149163 might improve working and reference memory in a
radial arm maze task. However, in the current study PD149163 did not significantly
increase or decrease working, reference, or total errors in the radial arm maze, alone or in
combination with MK801. The lack of evidence of PD149163’s ability to enhance
cognition might be a result of using the memory disruptive drug MK801 (see discussion
above).
PD149163 had no effect on path length, test session time, or velocity but did
significantly increase the percent of time spent immobile during a session. Even though
percent of time spent immobile was significantly increased, the overall test session time
was not increased and PD149163 was concluded to not have a significant effect on
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locomotor behavior in this study. In a different study, Azmi et al. (2006) reported no
difference in the total amount of time spent exploring the objects between drug groups in
a novel object discrimination task suggesting that there was no effect of PD149163 on
baseline exploratory behavior.
When comparing behavioral effects of neurotensin analogs to other antipsychotics
they appear to have a profile more similar to atypical antipsychotics than classical
antipsychotics, like haloperidol. For example, Hertel et al. (2002) tested the acute effects
of the neurotensin analog, NT69L (0.08, 0.16, 0.31 mg/kg s.c.) on conditioned avoidance
behavior, an assay with high predictive validity, and found it to be more similar to
atypical antipsychotics. Atypical antipsychotics reduce the percentages of avoidances
without increasing the number of escape failures, which is predictive of antipsychotic
drug efficacy. In the same study a typical antipsychotic, haloperidol (0.04, 0.08, 0.16
mg/kg, s.c.), suppressed the conditioned avoidance behavior and increase the number of
escape failures both acutely and chronically over a period of three weeks, producing
negative motor side effects. (Hertel, Olsen, & Arnt, 2002). NT69L, on the other hand,
failed to have an effect on conditioned avoidance behavior when administered
chronically (twice a day for at least 7 days), indicating that tolerance to neurotensin
analogs may develop after repeat administration (Hertel et al., 2002). Yet, the study still
suggests that neurotensin receptor agonists may stimulate beneficial antipsychotic-like
effects without creating adverse motor effects.
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Haloperidol
The typical antipsychotic, haloperidol, was chosen as a comparison drug to
PD149163 in the present study. Haloperidol modulates dopaminergic transmission but in
a different way than PD149163. Instead of indirectly modulating dopamine transmission,
haloperidol binds directly to the dopamine D2 receptors acting as an antagonist (Schotte
et al., 1996). By blocking D2 receptors, haloperidol decreases dopaminergic activity in
the prefrontal cortex and can negatively effect cognitive skills like processing speed and
procedural learning in humans (Woodward et al., 2005).
In the present study there was no main effect of haloperidol on number of errors
made alone or combination with MK801 Researchers using similar radial arm maze
tasks also found no effect of haloperidol alone on working memory errors (de Oliveira &
Nakamura-Palacios, 2003; Levin, 1997; Nagai et al., 2007; Terry et al., 2007; Wolff &
Leander, 2003). However, when given in combination with different memory disruptive
drugs haloperidol did increase memory errors. For example, haloperidol (3.2 mg/kg)
increased the disruptive effect of alcohol on a 1-hour delayed radial arm maze task (de
Oliveira & Nakamura-Palacios, 2003). Also, haloperidol (1 and 2 mg/kg) failed to
reverse a methamphetamine induced impairment in working memory in a delayed radial
arm maze task (Nagai et al., 2007).
Cognitive impairment by haloperidol may be related to motor depressive effects.
Haloperidol has been shown to reduce locomotor activity in rodents and produce a
significant increase in catalepsy when compared to vehicle at a relatively low dose (1.0
mg/kg) (Holly et al., 2010). Wolff and Leander (2003) found that haloperidol (1.0 and 3.0
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mg/kg) increased the test session time during the retention phase of a radial arm maze
task. Yet, in the current study haloperidol (0.03125 and 0.0625 mg/kg) did not
significantly effect path length, test session time, velocity, or percent of time spent
immobile. These results are important because they demonstrate that the doses of
haloperidol administered did not significantly affect locomotor behavior in any way.
Therefore, secondary effects of haloperidol on locomotor behavior can be eliminated as
an explanation for the memory effects observed.
Clozapine
Clozapine is also a weak antagonist of the dopamine D2 receptor and a strong
antagonist for the serotonin, 5-TH2A receptor, among many other receptors. This
combination of lower D2 / higher 5-HT receptor binding affinity and ability to increase
dopamine levels in the PFC is thought to be responsible for the cognitive enhancement
sometimes seen after the administration of atypical antipsychotics (Kuroki et al., 1999;
Woodward et al., 2005). A receptor type that clozapine activates, which other atypical
antipsychotics do not, are the M1 and M4 receptors (Roth et al., 2004). These receptors
stimulate the release of acetylcholine when activated and have been shown to improve
memory in animals (Woodward et al., 2005). A review of clinical studies with
schizophrenia patients revealed that clozapine improved attention and verbal fluency in
humans, but failed to improve working or spatial reference memory (Meltzer & McGurk,
1999).
In the present study there was no main effect of clozapine on the number of errors
made when it was administered with vehicle and with MK801. Researchers using a
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similar radial arm maze tasks also found no effect of clozapine on working memory
errors (Marcus et al., 2005; Nagai et al., 2007; Wolff & Leander, 2003). One study did
find that acute administration of clozapine (5, 10, 20 and 40 mg/kg, i.p.) significantly
increased working memory errors but this effect was diminished with chronic treatment
(Ortega-Alvaro et al., 2006). In addition, at least one study reported a reversal of MK801
induced deficits in working memory (counted as number of entries to repeat) by
clozapine (5mg/kg i.p.) which the current study failed to observe (Marcus et al., 2005).
Atypical antipsychotics like clozapine have been shown, at best, to mildly
improve some aspects of cognition in other human studies (Kaneda et al., 2010). In a
longitudinal study of schizophrenia patients, Kaneda et al. (2010) reported that clozapine
improved functioning on six out of nine cognitive measures. Meltzer and McGurk (1999)
have stated that atypical antipsychotics are better at improving cognitive function in
schizophrenia patients than typical antipsychotics. Yet, a review by Woodward et al.
(2005) concluded that no one atypical antipsychotic medication was better at improving
overall cognitive function than another and that even when improvements were made
they were mild. Research and development of atypical antipsychotics needs to continue
in search of a more holistic therapy option that treats all aspects of the disorder and not
just one type of symptom.
In the current study, clozapine had no main effect on path length, test session
time, velocity or percent of time spent immobile. These results demonstrate that the doses
of clozapine which were administered (0.3125 mg/kg and 1.25 mg/kg, s.c.) did not
significantly affect locomotor behavior in any way. This is important to note because
some studies report increasing test session time (5, 10, 20 and 40 mg/kg, i.p) and errors of
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omission with high doses (50 mg/kg, p.o) of clozapine (Ortega-Alvaro et al., 2006; Wolff
& Leander, 2003). Ortega-Alvaro (2006) also reported a decrease in distance travelled
after acute administration of clozapine (10, 20 and 40 mg/kg i.p.) These results suggest
that clozapine has a sedating effect on the motor system, which could be a result of its
affinity for H1 histamine receptors (Roth et al., 2004), but these symptoms were not
observed at the low doses of clozapine used in this study.
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SUMMARY AND CONCLUSIONS

Although this study did not find a significant improvement in memory following
administration of PD149163 it is worth noting that PD149163 did not impair any aspects
of memory either. It has been suggested that since PD149163 has a similar profile of
atypical antipsychotics it might be a novel antipsychotic that has therapeutic effects
without negatively effecting aspects of cognition like working and reference memory.
When evaluating novel antipsychotics researchers and doctors need to consider their
ability to improve cognition since cognitive impairment is a core symptom of
schizophrenia (Goldman-Rakic et al., 2004; Meltzer & McGurk, 1999; Silver et al., 2003;
Woodward et al., 2005). Cognitive impairments can be observed as deficits in executive
functions, working memory, verbal skills, processing speed and attention (Meltzer &
McGurk, 1999; Silver et al., 2003; Woodward et al., 2005). Improvements in these
cognitive domains are directly related to functional outcomes like employment and social
interaction skills (Kaneda et al., 2010; Meltzer & McGurk, 1999). Deficits in cognition
may predict long-term outcomes of people with schizophrenia and must be addressed
(Wolff & Leander, 2003). In addition, the search for a medication that will treat all
symptoms of schizophrenia and rehabilitate patients must continue.
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